UNIVERSITÉ PARIS DESCARTES
Patent Owner
Stats
- 0 US PATENTS IN FORCE
- 3 US APPLICATIONS PENDING
- Feb 01, 2018 most recent publication
Details
- 0 Issued Patents
- 0 Issued in last 3 years
- 0 Published in last 3 years
- 5 Total Citation Count
- Oct 14, 2011 Earliest Filing
- 4 Expired/Abandoned/Withdrawn Patents
Patent Activity in the Last 10 Years
Technologies
Intl Class
Technology
Matters
Rank in Class
Top Patents (by citation)
Upgrade to the Professional Level to View Top Patents for this Owner. Learn More |
Recent Publications
Publication #
Title
Filing Date
Pub Date
Intl Class
2018/0031,579 METHODS FOR PREDICTING THE RESPONSIVENESS OF A PATIENT AFFECTED WITH MALIGNANT HEMATOLOGICAL DISEASE TO CHEMOTHERAPY TREATMENT AND METHODS OF TREATMENT OF SUCH DISEASEFeb 11, 16Feb 01, 18[A61K, G01N, C07K]
2017/0320,939 COLL2-1 PEPTIDE AND ITS NITRATED FORM AS THERAPEUTIC TARGETS FOR OSTEOARTHRITIS TREATMENTJun 16, 17Nov 09, 17[A61K, C07K]
2016/0250,249 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING AUTOPHAGY IN A SUBJECT IN NEED THEREOFOct 03, 14Sep 01, 16[A61K]
Recent Patents
- No Recent Patents to Display
Expired/Abandoned/Withdrawn Patents
Patent #
Title
Status
Filing Date
Issue/Pub Date
Intl Class
2017/0027,860 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OCULAR INFLAMMATORY DISEASESAbandonedDec 01, 15Feb 02, 17[A61K]
2016/0281,176 METHOD FOR PREDICTING THE OUTCOME OF COLON CANCER BY ANALYSING MIRNA EXPRESSIONAbandonedMay 26, 16Sep 29, 16[C12Q]
2016/0143,867 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING CANCERAbandonedJun 20, 14May 26, 16[A61K]
2015/0342,876 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OCULAR INFLAMMATORY DISEASESAbandonedAug 11, 15Dec 03, 15[A61K]
Top Inventors for This Owner
Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More |
We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.